Abstract: Stable, aqueous emulsion formulations of water-insoluble organic pesticides are formed from a mixture of (1) a water-insoluble organic pesticide, (2) a water based structured particle latex containing nonionic particles to which is bound a layer containing stabilizing pH independent ionic groups chemically bound at or near the surface of the polymer particles, and optionally a cosolvent and/or cosurfactant for the pesticide. The resulting product is much more stable to coalescence than emulsions made with conventional surfactants.
Type:
Grant
Filed:
August 30, 1989
Date of Patent:
February 18, 1992
Assignee:
DowElanco
Inventors:
Ritchie A. Wessling, Dale M. Pickelman, Dennis G. Wujek
Abstract: All isomeric forms and mixtures of isomers of glutamic acid compounds of the formula ##STR1## wherein the glutamic aid is of D- or L- configuration, R.sub.1 is selected from the group consisting of hydrogen, alkyl of 1 to 5 carbon atoms, an amino acid, a peptide of 2 to 4 amino acids and an amino acid or a peptide of 2 to 4 amino acids in which the amine is esterified with an optionally unsaturated aliphatic carboxylic acid of 6 to 24 carbon atoms or R.sub.1 is selected from the group consisting of a residue of a C.sub.6 -C.sub.24 optionally unsaturated aliphatic acid. R.sub.5 is selected from the group consisting of hydrogen or an alkyl radical of 1 to 5 carbon atoms, R.sub.3 is selected from the group consisting of hydroxy, alkoxy of 1 to 5 carbon atoms, an amino acid with the amine optionally substituted with alkyl of 1 to 5 carbon atoms, Z is ##STR2## R.sub.2 is selected from the group consisting of hydrogen, an amino acid and a peptide of 2 to 4 amino acids, R.sub.
Type:
Grant
Filed:
February 26, 1988
Date of Patent:
February 18, 1992
Assignee:
Roussel Uclaf
Inventors:
Constantin Agouridas, Patrick Fauveau, Chantal Damais
Abstract: Disclosed are novel methods for inducing human ovulation by administering sequentially a plurality of recombinant FSH preparations, each of which have a distinguishable plasma half-life.
Type:
Grant
Filed:
March 17, 1989
Date of Patent:
February 11, 1992
Assignee:
Applied Research Systems ARS Holding N.V.
Abstract: Novel peptides having sulfate ester groups and containing 6 to 9 amino acids; possessing feeding inhibition properties and capable of stimulating the contraction of the gallbladder. Also methods of treating and preventing obesity in which these novel peptides or other specified peptides can be used.
Abstract: Disclosed herein are compounds of the class of peptides having from about 4 to about 8 amino acid residues that are substrates for retroviral protease, e.g., HIV protease, derived from known cleavage sites and that are modified to contain an internal COCH.sub.2 bond isostere, useful as inhibitors of said retroviral protease, e.g., HIV protease, and exemplified by the modified peptide, Abz-Thr-Ile-Nle.PSI.(K)Nle-Gln-Arg-NH.sub.2, wherein K is COCH.sub.2.
Abstract: A method for promoting regrowth of damaged nerve tissue in a mammal, the method comprising administering to the mammal a nerve tissue regrowth promoting amount of an LHRH antagonist namely, N-Acetyl -D-Naphthylalanine-D-para-Cl-Phe-D-Phe-Ser-Tyr-D-Arg-Phe-Arg-Pro-D-Ala-NH. sub.2.
Abstract: A polypeptide having the following formula is provided: gly-val-lys-gly-asp-lys-gly-asn-pro-gly-trp-pro-gly-ala-pro which has the ability to promote cellular adhesion, spreading the motility, while remaining highly cell specific. Medical applications such as chemodiagnostic and chemotherapeutic devices are also provided.
Type:
Grant
Filed:
December 14, 1989
Date of Patent:
January 21, 1992
Assignee:
Regents of the University of Minnesota
Inventors:
Mary K. Chelberg, Photini-Effie C. Tsilibary, James B. McCarthy
Abstract: Eclosion hormone (EH) was isolated and characterized using a variety of chromatographic techniques. EH is a polypeptide having 62 amino acids.
Type:
Grant
Filed:
January 22, 1991
Date of Patent:
January 21, 1992
Assignee:
Sandoz Ltd.
Inventors:
David A. Schooley, Hiroshi Kataoka, Steven J. Kramer
Abstract: The invention releates to a polypeptide of formula IR.sup.1 --CO--A.sup.1 --A.sup.2 --A.sup.3 A.sup.3 --A.sup.4 --A.sup.5 --A.sup.6 --Qwherein each of the generic terms is disclosed in full in the specification and includesR.sup.1 is a 5- or 6-membered unsaturated heterocyclic ring which contains one, two or three nitrogen atoms, which ring may optionally bear one or two substituents; a.sup.1 is a direct link to A.sup.2 ; or is His or D-His; A.sup.2 is Trp or MeTrp; A.sup.3 is Ala or MeAla; A.sup.4 is Val; A.sup.5 is Gly or D-Ala; A.sup.6 is His or Lys(Z); and Q is a group of the formula --A.sup.7.R.sup.2 in which A.sup.7 is Leu or LeMeu and R.sup.2 is hydroxy, amino, (1-3C)alkylamino or (1-3C)alkoxy; or Q is (1-6C)alkoxy or (1-10C)alkylamino.The compounds possess antagonist properties against bombesin-like peptides and are of value in treatment of malignant disease in warm-blooded animals.
Abstract: Purified human leukocyte dialysates are described for treatment of AIDS, ARC, and other immunodeficient conditions. The dialysates are purified by HPLC processes, and are made available in a form that is free of endotoxin and pyrogen. Methods are described for slowing the progression from ARC to AIDS and for alleviating symptoms of AIDS and ARC, by administration of the dialysates. Methods for treating candidiasis and for increasing immune system response to recall antigen, by administration of the dialysates, are also described.
Abstract: The present invention describes a method of preventing neutrophil chemotaxis, either in vitro or at a biological site using peptides whose amino acid sequence is derived at least in part from the sequence of native neutrophil activating factor (NAF). The peptides do not have measurable chemotactic activity against human neutrophils, but they are antagonistic to native NAF. The method of preventing neutrophil chemotaxis is practiced by adding sufficient amounts of the claimed peptides to neutrophils in a biological fluid or appropriate medium to inhibit neutrophil chemotaxis. The claimed peptides may have therapeutic value in patients with Adult Respiratory Distress Syndrome (ARDS) or with other inflammatory lesions known or found to be caused by NAF.
Type:
Grant
Filed:
February 5, 1990
Date of Patent:
January 7, 1992
Assignee:
Board of Regents, The University of Texas System
Inventors:
Allen B. Cohen, Edmund J. Miller, Shigeki Nagao, Ferdicia K. Carr
Abstract: The peptides of formula IA--x--Lys--y--B Iin which:A is H, a tripeptide of formula Arg-Ala-Arg or an hexapeptide of formula Glu-Lys-Arg-Arg-Ala-Arg x and y, different one from the other, are an arginine (Arg) or a glutamic acid (Glu) residue;B is OH or a tripeptide Arg-Ala-Arg with the proviso that when A is hydrogen and x is ARg, B is different from OH comprising the steps of:a) binding the Boc-protected carboxyterminal aminoacid to a suitable resin;b) reacting the other Boc-protected aminoacids with the resin-bound carboxyterminal aminoacid in the desired sequence;c) removing the protecting groups and releasing the so obtained peptides from the resin,have valuable pharmacological properties as immunostimulating agents.
Abstract: Composition and methods are disclosed for antagonizing SRS-A, and especially LTD.sub.4, comprising the administration of LXA.sub.4 or an active derivative thereof to an animal. These compositions and methods are useful in the control of hemostasis, vascular reactivity, and especially vasoconstriction, and anaphylactic and allergic reactions in animals.
Abstract: Synthesis of dolastatin 3 is accomplished by one amino acid unit addition from L-Pro-OMe employing diethyl phosphorocyanidate-triethylamine for peptide bond formation and N-Boc protection (trifluoroacetic acid cleavage). Thereafter Boc-L-Leu-L-(gln)Thz-(gly)Thz-L-Val-L-Pro-OMe was obtained, successively crystallized from ethanol-diethyl ether, converted to the OPfp active ester, Boc cleavage and cyclization in dioxane containing t-butanol and 4-pyrrolidinopyridine to yield synthetic (-)-dolastatin 3.
Abstract: Disclosed is a process by which a gas containing nitric oxide is contacted with an anaerobic microbial culture of denitrifying bacteria to effect the chemical reduction of the nitric oxide to elemental nitrogen. The process is particularly suited to the removal of nitric oxide from flue gas streams and gas streams from nitric acid plants. Thiobacillus dentrificians as well as other bacteria are disclosed for use in the process.
Abstract: A method of treating a mammal suffering from cancer by administering to the mammal somatostatin or an analog thereof, the analog being a hexapeptide analog or higher, in a dosage of at least 25 .mu.g/kg/day.
Type:
Grant
Filed:
August 11, 1988
Date of Patent:
December 17, 1991
Assignees:
Administrators of the Tulane Educational Fund, Biomeasure, Inc.
Inventors:
John E. Taylor, Arthur E. Bogden, Jacques-Pierre Moreau, David H. Coy
Abstract: CPF peptides and/or analogues or derivatives are used as a pharmaceutical. Such peptides have antibiotic and/or anti-viral and/or anti-tumor and/or anti-spermicidal activity.
Abstract: This invention relates to a solvent system for enhancing the solubility of an acidic, basic, or amphoteric pharmaceutical agent to produce a highly concentrated solution suitable for softgel filling or two piece encapsulation. The solvent system comprises polyethylene glycol containing 0.2-1.0 mole equivalents of an ionizing agent per mole equivalent pharmaceutical agent and 1-20% water. Glycerin or polyvinylpyrrolidone may be added to further enhance the solubility of certain drugs. The disclosed solvent system is capable of enhancing solubilities of pharmaceutical agents 40-400%.The ionizing agent functions by causing partial ionization (neutralization) of the free pharmaceutical agent. When the pharmaceutical agent is acidic, the ionizing agent is preferably a hydroxide ion species, whereas when the pharmaceutical agent is basic, the ionizing agent is preferably a hydrogen ion species.
Type:
Grant
Filed:
October 9, 1987
Date of Patent:
December 10, 1991
Assignee:
R. P. Scherer Corporation
Inventors:
Man S. Yu, Foo S. Hom, Sibaprasanna Chakrabarti, Chong-Heng Huang, Mahendra Patel
Abstract: The invention concerns certain orally active novel renin-inhibitory peptides which are useful for treating renin-associated hypertension, congestive heart failure, hyperaldosteronism, and glaucoma. It is also useful for treating diseases caused by retroviruses including HTLV-I, -II, and -III. Process for preparing the peptides, compositions containing them, and methods of using them are included. Also included is a diagnostic method which uses the compounds to determine the presence of renin-associated hypertension, congestive heart failure, or hyperaldosteronism.